This study will assess the impact of the novel oral hormonal agents (abiraterone acetate or
enzalutamide) among elderly metastatic prostate cancer patients. This study will assess the
influence of treatments on patients' cognitive functions on a longitudinal basis and evaluate
the quality of life and the adherence of patients who had or develop cognitive disorders.